Multiple Myeloma (MM), Lymphoma, Large B-Cell, Diffuse (DLBCL), LymphomaNCT07782944
CD38 Targeted -PET/ CT for Multiple Myeloma
A study testing standard-of-care imaging (FDG PET/CT), CD38 PET/CT in people with Multiple Myeloma (MM), Lymphoma, Large B-Cell, Diffuse (DLBCL), Lymphoma, run by Guilin Medical University, China at 1 site in China.
Trial summary
The objective of the study is to construct a noninvasive approach CD38 targeted PET/CT to detect tumor lesions in patients with Multiple Myeloma and to compare with FDG PET/CT. Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Multiple Myeloma (MM), Lymphoma, Large B-Cell, Diffuse (DLBCL), Lymphoma
- What is being tested?
- standard-of-care imaging (FDG PET/CT), CD38 PET/CT
- Type of treatment
- Injection or infusion
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 100 participants
- Where
- 1 siteChina
- Study dates
- 7 Jul 2026to 31 Dec 2030
- Phase
- Interventional
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Adult patients (aged 18 years or older);
- Patients with newly diagnosed, highly suspected recurrence or previously treated metastases of Multiple Myeloma (supporting evidence may include MRI, CT, tumor markers, and pathology report);
- Patients who had scheduled both standard-of-care imaging (FDG PET/CT) and cd38 PET/CT scans;
- Patients who were able to provide informed consent (signed by participant, parent or legal representative) and assent according to the guidelines of the Clinical Research Ethics Committee.
Who cannot join
- The inability or unwillingness of the research participant or legal representative to provide written informed consent.
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
Wei Fu contact
China1 site, 1 recruiting
- Recruiting
The First Affliated Hospital of Guilin Medical University
Guilin, Guangxi, 541001
Xingyu Mu, 86 13347631119, muxingyu1992@hotmail.com
About this study
Official title: Clinical Investigation of CD38-Targeted Molecular Imaging Probes in Multiple Myeloma
The objective of the study is to construct a noninvasive approach CD38 targeted PET/CT to detect tumor lesions in patients with Multiple Myeloma and to compare with FDG PET/CT.
Read the detailed description
CD38 targeting PET radiotracer is promising as an excellent imaging agent applicable to Multiple Myeloma. In this research, subjects with Multiple Myeloma or highly suspected recurrence detection underwent contemporaneous CD38 PET/CT and standard-of-care imaging (FDG PET/CT) either for an initial assessment or for metastases or highly suspected recurrence detection. Tumor uptake was quantified by the maximum standard uptake value (SUVmax). The numbers of positive tumor lesions of standard-of-care imaging and FDG PET/CT were recorded by visual interpretation. The diagnostic accuracy of CD38 PET/CT was calculated and compared to standard-of-care imaging.
- Being tested
- standard-of-care imaging (FDG PET/CT), CD38 PET/CT
- Keywords
- CD38, PET/CT, radiotracer, Multiple Myeloma
- Medical subject headings
- Multiple Myeloma, Lymphoma
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
standard-of-care imaging (FDG PET/CT), CD38 PET/CTDiagnostic test
Each subject receives a single intravenous injection of standard-of-care imaging radiopharmaceutical (FDG) and CD38, and undergoes PET/CT imaging within the specified time.
| Study group | Role | What they receive |
|---|---|---|
| CD38 PET/CT | Experimental | Each subject receives a single intravenous injection of radiolabeld CD38 and undergoes PET/CT imaging within the specified time. Receives: Diagnostic Test: standard-of-care imaging (FDG PET/CT), CD38 PET/CT |
What is being measured
The primary outcome is the main question the study is designed to answer.
Diagnostic efficacy
The sensitivity, specificity, and accuracy of standard-of-care imaging (FDG PET/CT) and CD38 PET/CT were calculated and compared to evaluate the diagnostic accuracy.
Measured: 3 year
Secondary outcomes (2)
Number of lesions
The numbers of positive primary and metastatic lesions of standard-of-care imaging (FDG PET/CT) and CD38 PET/CT were recorded by visual interpretation.
Measured: 3 year
SUV
Standardized uptake value (SUV) of standard-of-care imaging (FDG PET/CT) and CD38 PET/CT for each target lesion of subject or suspected primary tumor or/and metastasis.
Measured: 3 year
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted24 Aug 2026
- Study start7 Jul 2026
- Primary completion31 Dec 2030 (estimated)
- Study completion31 Dec 2030 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Multiple Myeloma (MM), Lymphoma, Large B-Cell, Diffuse (DLBCL), LymphomaStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Diagnosis
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Enrolment
- 100 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Guilin Medical University, China
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Wei Fu, Guilin Medical University, China
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07782944
- Sponsor's protocol ID
- 2025IITLL-10
- Status last verified
- Jul 2026
- First submitted
- 20 Aug 2026
- Last updated
- 24 Aug 2026
- Results posted
- No
- Data monitoring committee
- Yes
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 24 Aug 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Clinical Investigation of CD38-Targeted Molecular Imaging Probes in Multiple Myeloma
- ClinicalTrials.gov ID
- NCT07782944
- Acronym / sponsor ID
- 2025IITLL-10
- Keywords
- CD38, PET/CT, radiotracer, Multiple Myeloma
- Study type
- Interventional
- Recruitment status
- Recruiting
- Enrolment
- 100 participants (estimated)
- Lead sponsor
- Guilin Medical University, ChinaUniversity, hospital or other
- Study start
- 7 Jul 2026 (actual)
- Primary completion
- 31 Dec 2030 (estimated)
- Study completion
- 31 Dec 2030 (estimated)
- First posted
- 24 Aug 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The objective of the study is to construct a noninvasive approach CD38 targeted PET/CT to detect tumor lesions in patients with Multiple Myeloma and to compare with FDG PET/CT.
Detailed description
CD38 targeting PET radiotracer is promising as an excellent imaging agent applicable to Multiple Myeloma. In this research, subjects with Multiple Myeloma or highly suspected recurrence detection underwent contemporaneous CD38 PET/CT and standard-of-care imaging (FDG PET/CT) either for an initial assessment or for metastases or highly suspected recurrence detection. Tumor uptake was quantified by the maximum standard uptake value (SUVmax). The numbers of positive tumor lesions of standard-of-care imaging and FDG PET/CT were recorded by visual interpretation. The diagnostic accuracy of CD38 PET/CT was calculated and compared to standard-of-care imaging.
Study design
- Primary purpose
- Diagnosis
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| CD38 PET/CT | Experimental | Diagnostic Test: standard-of-care imaging (FDG PET/CT), CD38 PET/CTEach subject receives a single intravenous injection of radiolabeld CD38 and undergoes PET/CT imaging within the specified time. |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (4 listed)
- Adult patients (aged 18 years or older);
- Patients with newly diagnosed, highly suspected recurrence or previously treated metastases of Multiple Myeloma (supporting evidence may include MRI, CT, tumor markers, and pathology report);
- Patients who had scheduled both standard-of-care imaging (FDG PET/CT) and cd38 PET/CT scans;
- Patients who were able to provide informed consent (signed by participant, parent or legal representative) and assent according to the guidelines of the Clinical Research Ethics Committee.
Key exclusion criteria (1 listed)
- The inability or unwillingness of the research participant or legal representative to provide written informed consent.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| standard-of-care imaging (FDG PET/CT), CD38 PET/CTEach subject receives a single intravenous injection of standard-of-care imaging radiopharmaceutical (FDG) and CD38, and undergoes PET/CT imaging within the specified time. | Diagnostic test | CD38 PET/CT |
Primary outcome
Diagnostic efficacy
Time frame: 3 year
The sensitivity, specificity, and accuracy of standard-of-care imaging (FDG PET/CT) and CD38 PET/CT were calculated and compared to evaluate the diagnostic accuracy.
2 secondary outcomes
Number of lesions
Time frame: 3 year
SUV
Time frame: 3 year
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 24 Aug 2026.
- Individual participant dataSharing planned: No
Related trials for Multiple Myeloma (MM), Lymphoma, Large B-Cell, Diffuse (DLBCL), Lymphoma
RecruitingPhase 1
Low-Dose TBI Plus CAR T-Cell Therapy for Relapsed/Refractory DLBCL and Multiple Myeloma
Relapsed or Refractory Diffuse Large B Cell Lymphoma (DLBCL), Relapsed or Refractory Multiple Myeloma (MM)
Not yet recruitingObservational study
Why Patients Decline or Are Being Deemed Ineligible to Receive Home-based Treatment: a Mixed Methods Study
Multiple Myeloma (MM), Lymphoma, Large B-Cell, Diffuse (DLBCL), Lymphoma, Multiple Myeloma Progression
Not yet recruitingPhase 2/3
Early Prophylactic rhTPO Administration for Thrombocytopenia Associated With EAP Regimen-Based Hematopoietic Stem Cell Mobilization
Multiple Myeloma (MM), Lymphoma, Large B-Cell, Diffuse (DLBCL), Lymphoma, Hematopoietic Stem Cell Mobilization
Active, not recruiting
A Manualised Post-Traumatic Growth Intervention For People With Hematological Cancers In Greece
Blood Cancers, Leukemia
Not yet recruitingPhase 2
BAFF CAR-T Cells (LMY-920) for Treatment of Relapsed or Refractory Non-Hodgkin Lymphoma and Multiple Myeloma
Non-Hodgkin Lymphoma Refractory/ Relapsed, Multiple Myeloma Refractory
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
Wei Fu contact
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing standard-of-care imaging (FDG PET/CT), CD38 PET/CT in people with Multiple Myeloma (MM), Lymphoma, Large B-Cell, Diffuse (DLBCL), Lymphoma, run by Guilin Medical University, China at 1 site in China.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 4 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 24 Aug 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in China. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Xingyu Mu, M.D. (86 13347631119, muxingyu1992@hotmail.com), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Diagnostic efficacy (time frame: 3 year). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 24 Aug 2026; AzTrials last refreshed its copy on 30 Oct 2026.